Search results
Updated Covid-19 Vaccine Targeting JN.1 Recommended By FDA Panel
Forbes· 5 days agoThe Vaccines and Related Biological Products Advisory Committee of the FDA evaluated the...
Merck, Moderna Drug Combo Shows Improved Survival in Skin Cancer Trial
Morningstar· 6 days agoModerna and Merck said they saw positive results from a Phase 2b study evaluating mRNA-4157 in combination with Keytruda in patients with high-risk skin cancer that was surgically ...
Moderna's RSV Vaccine Approved by FDA
Medscape· 7 days agoFor the first time, an mRNA vaccine has been approved for an indication other than COVID-19. The vaccine will join a couple other immunizations currently on the market for respiratory syncytial virus.
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R)...
Digital Journal· 6 days agoAt a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis ...
COVID vaccine makers ready updated shots for fall immunization drive (NYSE:PFE)
Seeking Alpha· 4 days agoPfizer (PFE), BioNTech (BNTX), Moderna (MRNA) and Novavax (NVAX) reaffirm commitment to provide...
FDA clears GSK's RSV vaccine for adults ages 50-59
United Press International via Yahoo News· 24 hours agoThe U.S. Food and Drug Administration on Friday approved GSK's respiratory syncytial virus vaccine for high-risk adults ages 50 to 59, expanding the...
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
Benzinga· 5 days agoOn Friday, Pfizer Inc PFE revealed its drug for an advanced form of lung cancer showed promising...
FDA Green-Lights Moderna Vaccine for Older Adults | Newswise
Newswise· 4 days agoThe US Food and Drug Administration has approved Moderna’s mRNA vaccine for older adults to protect against respiratory syncytial virus (RSV). According to a company press ...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 2 days agoIn 2020, the industry was thrust into the pandemic limelight as Pfizer and its partner BioNTech,...
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 2 days agoThe vaccine is based on protein technology, differentiating it from Pfizer's and Moderna's messenger...
